
Sign up to save your podcasts
Or


In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.
Featured Articles:
By American Society of Hematology4.1
4949 ratings
In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.
Featured Articles:

11,155 Listeners

139 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,156 Listeners

2 Listeners

363 Listeners

372 Listeners

1 Listeners

48 Listeners

189 Listeners

30 Listeners

4 Listeners